JP2014509868A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509868A5 JP2014509868A5 JP2014501270A JP2014501270A JP2014509868A5 JP 2014509868 A5 JP2014509868 A5 JP 2014509868A5 JP 2014501270 A JP2014501270 A JP 2014501270A JP 2014501270 A JP2014501270 A JP 2014501270A JP 2014509868 A5 JP2014509868 A5 JP 2014509868A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- seq
- level
- kit
- gene product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 42
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 108091034117 Oligonucleotide Proteins 0.000 claims description 16
- 239000000523 sample Substances 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 238000003757 reverse transcription PCR Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 238000010208 microarray analysis Methods 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims description 2
- 238000005481 NMR spectroscopy Methods 0.000 claims description 2
- 238000000636 Northern blotting Methods 0.000 claims description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 239000000090 biomarker Substances 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 238000003119 immunoblot Methods 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000007481 next generation sequencing Methods 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 239000002751 oligonucleotide probe Substances 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 238000010839 reverse transcription Methods 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 238000004885 tandem mass spectrometry Methods 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 238000003196 serial analysis of gene expression Methods 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 238000001502 gel electrophoresis Methods 0.000 claims 1
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 102000028756 CDC20 Human genes 0.000 description 1
- 108700020472 CDC20 Proteins 0.000 description 1
- 101150023302 Cdc20 gene Proteins 0.000 description 1
- 102100024479 Cell division cycle-associated protein 3 Human genes 0.000 description 1
- 102100037753 DEP domain-containing protein 1A Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000055341 HMGB2 Human genes 0.000 description 1
- 101000980907 Homo sapiens Cell division cycle-associated protein 3 Proteins 0.000 description 1
- 101000950642 Homo sapiens DEP domain-containing protein 1A Proteins 0.000 description 1
- 101001045791 Homo sapiens High mobility group protein B2 Proteins 0.000 description 1
- 101001008953 Homo sapiens Kinesin-like protein KIF11 Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101000743825 Homo sapiens Protein zwilch homolog Proteins 0.000 description 1
- 101000830894 Homo sapiens Targeting protein for Xklp2 Proteins 0.000 description 1
- 102100027629 Kinesin-like protein KIF11 Human genes 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102100039105 Protein zwilch homolog Human genes 0.000 description 1
- 101100010298 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pol2 gene Proteins 0.000 description 1
- 102100024813 Targeting protein for Xklp2 Human genes 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467999P | 2011-03-26 | 2011-03-26 | |
| US61/467,999 | 2011-03-26 | ||
| PCT/US2012/030309 WO2012135008A1 (en) | 2011-03-26 | 2012-03-23 | Gene expression predictors of cancer prognosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014509868A JP2014509868A (ja) | 2014-04-24 |
| JP2014509868A5 true JP2014509868A5 (enExample) | 2015-05-07 |
Family
ID=46931859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501270A Pending JP2014509868A (ja) | 2011-03-26 | 2012-03-23 | 癌の予後のための遺伝子発現予測因子 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20140113297A1 (enExample) |
| EP (1) | EP2691547A4 (enExample) |
| JP (1) | JP2014509868A (enExample) |
| CA (1) | CA2831074A1 (enExample) |
| WO (1) | WO2012135008A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| CA2725978A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| EP2591126B1 (en) | 2010-07-07 | 2020-12-30 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| WO2012030840A2 (en) | 2010-08-30 | 2012-03-08 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| EP2791359B1 (en) | 2011-12-13 | 2020-01-15 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| JP2015522277A (ja) * | 2012-06-28 | 2015-08-06 | カルドラ ヘルス リミテッドＣａｌｄｅｒａ Ｈｅａｌｔｈ Ｌｔｄ | 前立腺癌の診断方法と診断用物質 |
| AU2013302365B2 (en) | 2012-08-16 | 2019-03-21 | Mayo Foundation For Medical Education And Research | Cancer diagnostics using biomarkers |
| ES2938766T3 (es) | 2012-11-16 | 2023-04-14 | Myriad Genetics Inc | Firmas génicas para el pronóstico de cáncer |
| EP2971177B1 (en) * | 2013-03-14 | 2019-09-11 | Neogenomics Laboratories, Inc. | Compositions and methods for detecting and determining a prognosis for prostate cancer |
| WO2014159443A1 (en) * | 2013-03-14 | 2014-10-02 | Genomedx Biosciences, Inc. | Cancer biomarkers and classifiers and uses thereof |
| EP3143160B1 (en) | 2014-05-13 | 2019-11-06 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| WO2017062505A1 (en) | 2015-10-05 | 2017-04-13 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
| EP3504348B1 (en) | 2016-08-24 | 2022-12-14 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| CA3050984A1 (en) | 2017-01-20 | 2018-07-26 | Decipher Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
| CA3055925A1 (en) | 2017-03-09 | 2018-09-13 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| CA3062716A1 (en) | 2017-05-12 | 2018-11-15 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness |
| WO2019028285A2 (en) | 2017-08-04 | 2019-02-07 | Genomedx, Inc. | USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY |
| US11083127B2 (en) | 2018-05-09 | 2021-08-10 | Deere & Company | Seeding machine to provide transverse tramlines |
| US20230323466A1 (en) * | 2020-07-15 | 2023-10-12 | Queensland University Of Technology | Determining cancer responsiveness to treatment |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3330875B1 (en) * | 2003-07-10 | 2021-12-01 | Genomic Health, Inc. | Expression profile algorithm and test for prognosing breast cancer recurrence |
| US20080275652A1 (en) * | 2005-05-13 | 2008-11-06 | Universite Libre De Bruxelles | Gene-based algorithmic cancer prognosis |
| US7914988B1 (en) * | 2006-03-31 | 2011-03-29 | Illumina, Inc. | Gene expression profiles to predict relapse of prostate cancer |
| WO2008021290A2 (en) * | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| US8470534B2 (en) * | 2006-12-01 | 2013-06-25 | Erik S. Knudsen | Methods of predicting resistance or sensitivity to therapies for cancer |
| CA2725978A1 (en) * | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US20090298082A1 (en) * | 2008-05-30 | 2009-12-03 | Klee George G | Biomarker panels for predicting prostate cancer outcomes |
| CA2730277A1 (en) * | 2008-07-08 | 2010-01-14 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for predicting the survivability of prostate cancer subjects |
| EP3118328A1 (en) * | 2009-01-07 | 2017-01-18 | Myriad Genetics, Inc. | Cancer biomarkers |
| WO2010129965A1 (en) * | 2009-05-08 | 2010-11-11 | The Regents Of The University Of California | Cancer specific mitotic network |
| CA2776751C (en) * | 2009-11-23 | 2019-07-02 | Genomic Health, Inc. | Methods to predict clinical outcome of cancer |
| EP2591126B1 (en) * | 2010-07-07 | 2020-12-30 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
-
2012
- 2012-03-23 US US14/007,527 patent/US20140113297A1/en not_active Abandoned
- 2012-03-23 WO PCT/US2012/030309 patent/WO2012135008A1/en not_active Ceased
- 2012-03-23 EP EP12765325.1A patent/EP2691547A4/en not_active Withdrawn
- 2012-03-23 JP JP2014501270A patent/JP2014509868A/ja active Pending
- 2012-03-23 CA CA2831074A patent/CA2831074A1/en not_active Abandoned
-
2016
- 2016-02-18 US US15/047,533 patent/US20160168649A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509868A5 (enExample) | ||
| Maltseva et al. | High-throughput identification of reference genes for research and clinical RT-qPCR analysis of breast cancer samples | |
| Hung et al. | Diverse roles of hnRNP L in mammalian mRNA processing: a combined microarray and RNAi analysis | |
| KR101562644B1 (ko) | 직장결장암용 예후 예측 | |
| Ballester et al. | Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas | |
| ES2525382T3 (es) | Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino | |
| Linton et al. | Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours | |
| KR20140105836A (ko) | 다유전자 바이오마커의 확인 | |
| JP2006506945A (ja) | 遺伝子発現プロフィールを使用する非小細胞肺癌の診断および処置のための方法および組成物 | |
| JP2019004907A (ja) | メラノーマ癌の予後予測 | |
| CA3043089A1 (en) | Methods to predict clinical outcome of cancer | |
| SG192108A1 (en) | Colon cancer gene expression signatures and methods of use | |
| AU2004211955A1 (en) | Gene expression markers for response to EGFR inhibitor drugs | |
| JP2014522665A (ja) | びまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）患者における抗−ｃｄ２０療法に対する応答の予測 | |
| JP2014509868A (ja) | 癌の予後のための遺伝子発現予測因子 | |
| US20160186270A1 (en) | Signature of cycling hypoxia and use thereof for the prognosis of cancer | |
| Wu et al. | Systematic analysis of transcribed loci in ENCODE regions using RACE sequencing reveals extensive transcription in the human genome | |
| Zhang et al. | Comprehensive analysis of prognostic value of MEX3A and its relationship with immune infiltrates in ovarian cancer | |
| WO2015127101A1 (en) | Method and composition for diagnosis of aggressive prostate cancer | |
| US20180046754A1 (en) | Normalization methods for measuring gene copy number and expression | |
| CN108474041A (zh) | 使用遗传标记的甲基化状态区分转移性-致死性前列腺癌与惰性前列腺癌 | |
| EP3196316B1 (en) | METHOD AND DEVICE FOR COMPARATIVE ANALYSIS OF miRNA EXPRESSION LEVEL | |
| US20230340611A1 (en) | Biomarkers For Immune Checkpoint Inhibitors Treatment | |
| Nagy et al. | miRNA isolation from FFPET specimen: a technical comparison of miRNA and total RNA isolation methods | |
| Rajawat | Transcriptomics |